<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516395</url>
  </required_header>
  <id_info>
    <org_study_id>Q011h/63</org_study_id>
    <nct_id>NCT04516395</nct_id>
  </id_info>
  <brief_title>Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae</brief_title>
  <official_title>Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae: the Study of in Vitro Activity of Monotherapy and Combination Therapy, PK/PD Study and Treatment Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the treatment outcomes in patients with CRE&#xD;
      infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibiotic resistance is one of the major problems because of global burden. Resistant&#xD;
      pathogens are non-susceptible to available antibiotics, causing of high clinical mortality&#xD;
      (clinical impact) and high budget (economic impact), whereas new antibiotics in drug&#xD;
      development are fewer. Carbapenem-Resistant Enterobacteriaceae (CRE) are categorized into one&#xD;
      of the critical groups in World Health Organization's lists. In Thailand, the spread of CRE&#xD;
      have been risen continuously since 2011.&#xD;
&#xD;
      Diverse actions are designed to address antibiotic resistance with limited resources, known&#xD;
      as antimicrobial stewardship programs (ASPs). Dose-optimization by using PK/PD&#xD;
      (Pharmacokinetics/Pharmacodynamics) application is recommendation of supplemental strategies&#xD;
      in clinical routine practice. The benefit of the strategy is to reduce inappropriate&#xD;
      antibiotic use and provide minimum resistance as well as maximum the success of clinical&#xD;
      treatment.&#xD;
&#xD;
      Antibiotic combination regimens have a role for the CRE treatment. However, current evidence&#xD;
      in clinical study is not concluded which the best or optimal combined antibiotics are. The&#xD;
      reasons may be that combined antibiotics often vary among different sites of infection,&#xD;
      causative pathogens, the patterns of local antimicrobial susceptibility and patient&#xD;
      comorbidity. As the results, the antibiotic combination regimens for the treatment any&#xD;
      infections caused by CRE is needed for further investigation. The anticipated result is to&#xD;
      fill the limited data of the appropriate antibiotic regimens for individual Thai patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>According to the model, it divided into two parts - retrospective chart review and prospective data collection. Single independent patient group will be divided two parts depending on over a period of time. The patients in the retrospective part received a standard treatment become a control group, while the patients in the prospective part received the intervention become an experimental group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement or failure</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Clinical improvement was defined as resolution of the signs and symptoms of the infection with no change or addition antibiotic therapy at the end of treatment course, excepting de-escalation to a narrower spectrum antibiotic.&#xD;
Clinical failure was defined as the signs and symptoms of the infection being more serious with change or addition antibiotic therapy against CRE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Within 14 and 28/30 days after discharge</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>The duration of a hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician acceptance rates</measure>
    <time_frame>up to 72 hours after reporting the bacterial culture results</time_frame>
    <description>The rates of physicians' acceptance of an recommended optimal regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological outcomes</measure>
    <time_frame>Before discharge</time_frame>
    <description>Bacterial response in cultures after the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Drug Resistance</condition>
  <condition>Carbapenem-Resistant Enterobacteriaceae Infection</condition>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Critical Illness</condition>
  <condition>Clinical Outcomes</condition>
  <condition>Treatment Outcomes</condition>
  <arm_group>
    <arm_group_label>Optimal antibiotic combination regimens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in the groups will be given the optimal antibiotic combination regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard antibiotic regimens</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients in the groups will be given the standard antibiotic regimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Combined antibiotic regimens</intervention_name>
    <description>Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.</description>
    <arm_group_label>Optimal antibiotic combination regimens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard antibiotic regimens</intervention_name>
    <description>Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.</description>
    <arm_group_label>Standard antibiotic regimens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any patients are diagnosed any diseases caused by CRE infection by physicians at&#xD;
             Phramongkutklao hospital during 1/4/2018 to 30/4/2021.&#xD;
&#xD;
          2. Any patients are more than 18 years old.&#xD;
&#xD;
          3. Any patients have at least 1 criterion as following 3.1 Any patients have at least 2&#xD;
             of the signs and symptoms of Systemic inflammatory response syndrome (SIRS), including&#xD;
&#xD;
               -  Fever (temperature &gt; 38 °C) or hypothermia (temperature &lt; 36°C)&#xD;
&#xD;
               -  Tachypnea (heart rate &gt; 90 beats per minute)&#xD;
&#xD;
               -  Respiratory rate &gt; 20 beats per minute or Paco2 &lt; 32 mm Hg (4.3 kPa)&#xD;
&#xD;
               -  White blood cell count &gt; 12,000 cells per millilitre (leukocytosis) or &lt; 4,000&#xD;
                  cells per milliliter (leukopenia) 3.2. Any patients are diagnosed with sepsis or&#xD;
                  have ≥ 2 points of Sequential Organ Failure Assessment (SOFA) Score or qSOFA&#xD;
                  (Quick SOFA) Score.&#xD;
&#xD;
        3.3. Any patients are diagnosed with septic shock or are received vasopressors (eg,&#xD;
        dopamine, norepinephrine, epinephrine, vasopressin, phenylephrine), mean arterial pressure&#xD;
        (MAP) &lt; 65 mm Hg, and lactate &gt; 2 mmol/L (18 mg/dL) 3.4 Any patients are received&#xD;
        mechanical ventilation 3.5 Any patients are admitted at ICU ward.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are breast-feeding or pregnancy.&#xD;
&#xD;
          2. Patients are insufficient or incomplete information on the medical electronic record&#xD;
             such as patients transferred.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wichai Santimaleeworagun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Silpakorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wichai Santimaleeworagun, PhD</last_name>
    <phone>663547600</phone>
    <email>Swichai1234@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phramongkutklao hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Parnrada Nulsopapon</last_name>
      <phone>667633120</phone>
      <email>aom.olivegreen1812@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wichai Santimaleeworagun</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manat Pongchaidecha</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maj. Worapong Nasomsong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parnrada Nulsopapon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://narst.dmsc.moph.go.th/data/AMR%202000-2019-06M.pdf</url>
    <description>Drug resistance situations from National Antimicrobial Resistance Surveillance Center Thailand (NARST) (Thai)</description>
  </link>
  <results_reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </results_reference>
  <results_reference>
    <citation>Tillotson G. A crucial list of pathogens. Lancet Infect Dis. 2018 Mar;18(3):234-236. doi: 10.1016/S1473-3099(17)30754-5. Epub 2017 Dec 21.</citation>
    <PMID>29276050</PMID>
  </results_reference>
  <results_reference>
    <citation>Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016 May 15;62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13.</citation>
    <PMID>27080992</PMID>
  </results_reference>
  <results_reference>
    <citation>Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. J Infect Chemother. 2015 May;21(5):319-29. doi: 10.1016/j.jiac.2015.02.001. Epub 2015 Feb 12. Review.</citation>
    <PMID>25737147</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018 Feb 14;31(2). pii: e00079-17. doi: 10.1128/CMR.00079-17. Print 2018 Apr. Review.</citation>
    <PMID>29444952</PMID>
  </results_reference>
  <results_reference>
    <citation>Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, Simner PJ. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis. 2017 Feb 1;64(3):257-264. doi: 10.1093/cid/ciw741. Epub 2016 Nov 9.</citation>
    <PMID>28013264</PMID>
  </results_reference>
  <results_reference>
    <citation>Demidenko E, Miller TW. Statistical determination of synergy based on Bliss definition of drugs independence. PLoS One. 2019 Nov 25;14(11):e0224137. doi: 10.1371/journal.pone.0224137. eCollection 2019.</citation>
    <PMID>31765385</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. Front Microbiol. 2019 Jan 30;10:80. doi: 10.3389/fmicb.2019.00080. eCollection 2019. Review.</citation>
    <PMID>30761114</PMID>
  </results_reference>
  <results_reference>
    <citation>Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22.</citation>
    <PMID>28442293</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 22, 2020</last_update_submitted>
  <last_update_submitted_qc>August 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics/Pharmacodynamics</keyword>
  <keyword>Antibiotic combination regimens</keyword>
  <keyword>Dose-optimization</keyword>
  <keyword>Carbapenem-Resistant Enterobacteriaceae Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

